ArticleJournal of cellular and molecular medicine2025
Modified Qianghuo Shengshi Decoction Ameliorates Osteoarthritis via Inhibiting PI3K/Akt Pathway-Related Ferroptosis.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Modified Qianghuo Shengshi Decoction Ameliorates Osteoarthritis via Inhibiting PI3K/Akt Pathway-Related Ferroptosis.Journal of cellular and molecular medicine · 2025Article
- Astragaloside IV Alleviates Osteoarthritis by Inhibiting Chondrocyte Ferroptosis via the p53/SLC7A11/GPX4 Axis.Journal of inflammation research · 2025Article
- Glutathione peroxidase 4 as an emerging therapeutic target in osteoarthritis: focus on ferroptosis.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Modified Qianghuo Shengshi decoction (MQSD), a TCM formula, is clinically used for osteoarthritis (OA) symptom relief. Its exact molecular actions, however, are not fully understood. This investigation seeks to elucidate the molecular mechanisms by which MQSD impedes OA progression. High performance liquid chromatography (HPLC) was employed to delineate MQSD's chemical profile. The CCK-8 assay determined MQSD's impact on chondrocyte viability in the presence or absence of IL-1β. EDU and Annexin V-FITC assays evaluated chondrocyte proliferation and apoptosis, respectively. Alcian Blue staining probed extracellular matrix (ECM) secretion by chondrocytes. Network pharmacology was utilised to pinpoint disease targets, while various assays assessed ferroptosis-related chondrocyte phenotypes under Erastin or Ferrostatin-1 treatments. IHC, qRT-PCR and western blot analyses were conducted to ascertain MQSD's cellular effects. Micro-CT and Safranin O Fast Green staining provided insights into knee joint morphology and cartilage integrity. Molecular docking assessed the binding affinity of MQSD's active compounds to PI3K/Akt/GPX4. MQSD promotes chondrocyte proliferation, prevents apoptosis, and enhances viability. It further modulates the ECM output and the anabolic-to-catabolic ratio within chondrocytes. Through network pharmacology, ferroptosis linked to the PI3K/Akt pathway is identified as crucial. Pre-application of MQSD elevates the GSH/GSSG ratio and mitochondrial density, while it reduces Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.